Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ursodiol 500mg Tablets Under Fed Conditions
NCT03512821Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ursodeoxycholic acid in primary biliary cholangitis (PBC) and cholelithiasis (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area under the plasma concentration versus time curve. Started Oct 2017; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)cholelithiasis
Beyond the preview
Go deeper on NCT03512821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512821.